Your Trusted GLP-1 Resource
Evidence-based guides on Ozempic, Wegovy, and Mounjaro. Side effects, diet plans, dosage guides, and the latest research — written by medical reviewers and backed by clinical trials.
Start here:
Introduction If you’re starting Ozempic (semaglutide) — or considering it — you’ve probably heard about the side effects. And they’re real. But understanding what’s normal, what’s manageable, and what’s a red flag can make the difference between a successful treatment journey and giving up too soon. This guide draws on peer-reviewed clinical trials, FDA adverse event data, and real patient experiences to give you the clearest picture available in 2026. ...
Introduction The two heavyweight champions of GLP-1 weight loss — Ozempic (semaglutide) and Mounjaro (tirzepatide) — dominate the conversation in 2026. But which one should you choose? This comparison is based on head-to-head clinical trials, real-world data, and 2026 pricing and insurance information. We’ll cover effectiveness, side effects, cost, and practical considerations to help you make an informed decision with your doctor. Quick Comparison: At a Glance Feature Ozempic (Semaglutide) Mounjaro (Tirzepatide) Drug Class GLP-1 receptor agonist Dual GIP/GLP-1 receptor agonist Manufacturer Novo Nordisk Eli Lilly FDA Approved For Type 2 diabetes (2017); Weight loss as Wegovy (2021) Type 2 diabetes (2022); Weight loss as Zepbound (2023) Dosing Frequency Once weekly Once weekly Max Dose for Weight Loss 2.4 mg (Wegovy) 15 mg (Zepbound) Average Weight Loss at Max Dose ~15% of body weight ~21-23% of body weight Administration Prefilled pen Single-dose pen (autoinjector) Effectiveness: Mounjaro Wins — But by How Much? The SURMOUNT-1 Trial (Mounjaro/Zepbound) In the landmark SURMOUNT-1 trial, participants taking the highest dose of tirzepatide (15 mg) lost an average of 22.5% of their body weight over 72 weeks. At the 10 mg dose, average weight loss was 21.4%. ...